Date: 2015-05-20
Type of information: Construction of a production plant
Compound:
Company: CMC Biologics (Denmark - USA)
Therapeutic area: Technology - Services
Type agreement: expansion of a production plant
Action mechanism:
Disease:
Details: * On May 20, 2015, CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced that as part of its global manufacturing capacity expansion strategy, it will add approximately 14,000 liters of additional manufacturing capacity to its Copenhagen, Denmark facility. Customers will soon have greater flexibility in the manufacture of large-scale, late-stage and commercial products through CMC Biologics’ innovative single-use Bioreactor 6PackTM facility design. The Bioreactor 6Pack™ configuration consists of six 2000L production bioreactors in one manufacturing line, allowing for flexible production with scales from 2,000L to 14,000L in a single production suite. The bioreactors can be run singly or in groups, simultaneously, sequentially or in staggered fashion to achieve production needs. The Copenhagen installation, scheduled for initial GMP production in November 2015, will consist of a Bioreactor 3Pack™ configuration consisting of a seed train and three 2,000L single-use production bioreactors. Three additional 2,000L bioreactors will be added at a later date to complete the Bioreactor 6Pack™ line. The company has completed construction of the Bioreactor 6Pack™ in the Seattle facility and will conduct the first GMP run mid-2015, and will be in full production for a commercial launch later this year.
Financial terms:
Latest news:
